The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment

被引：71
作者：
Cheng, W. W. [2 ,3 ]
Allen, T. M. [1 ,4 ]
机构：
[1] Univ Alberta, Dept Pharmacol, Fac Med & Dent, Edmonton, AB T6G 2H7, Canada
[2] Univ Alberta, Dept Pharmacol, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2H7, Canada
[3] Univ Alberta Hosp, Dept Pharm, Alberta Hlth Serv, Edmonton, AB T6G 2B7, Canada
[4] Univ British Columbia, Ctr Drug Res & Dev, Vancouver, BC V6T 1Z4, Canada
来源：
EXPERT OPINION ON DRUG DELIVERY | 2010年 / 7卷 / 04期
关键词：
STERICALLY STABILIZED LIPOSOMES; B-CELL LYMPHOMA; PROLONGED CIRCULATION TIME; ANTIBODY SCFV FRAGMENTS; FUSION PROTEIN MFECP1; NON-HODGKINS-LYMPHOMA; IN-VITRO; ESCHERICHIA-COLI; ANTIGEN-BINDING; MONOCLONAL-ANTIBODY;
D O I：
10.1517/17425240903579963
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered in this review: This review is focused mainly on advances in scFv-targeted liposomal drug delivery for the treatment of cancers, based on a survey of the recent literature, and on experiments done in a murine model of human B-lymphoma, using anti-CD19 targeted liposomes targeted with whole mAb, Fab' fragments and scFv fragments. What the reader will gain: This review examines the recent advances in PEGylated immunoliposomal drug delivery, focusing on scFv fragments as targeting agents, in comparison with Fab' and mAb. Take home message: For clinical development, scFv are potentially preferred targeting agents for PEGylated liposomes over mAb and Fab', owing to factors such as decreased immunogenicity, and pharmacokinetics/biodistribution profiles that are similar to non-targeted PEGylated (Stealth<SU (R)</SU) liposomes.
引用
收藏
页码：461 / 478
页数：18
相关论文
共 165 条
[1]   In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading [J].
Abraham, SA ;
McKenzie, C ;
Masin, D ;
Ng, R ;
Harasym, TO ;
Mayer, LD ;
Bally, MB .
CLINICAL CANCER RESEARCH, 2004, 10 (02) :728-738
[2]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[3]  
ADLERMOORE J, 1994, BONE MARROW TRANSPL, V14, pS3
[4]  
Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121
[5]   Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates [J].
Allen, TM ;
Mumbengegwi, DR ;
Charrois, GJR .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3567-3573
[6]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[7]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[8]   A NEW STRATEGY FOR ATTACHMENT OF ANTIBODIES TO STERICALLY STABILIZED LIPOSOMES RESULTING IN EFFICIENT TARGETING TO CANCER-CELLS [J].
ALLEN, TM ;
BRANDEIS, E ;
HANSEN, CB ;
KAO, GY ;
ZALIPSKY, S .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1237 (02) :99-108
[9]   Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies [J].
An, Feng ;
Drummond, Daryl C. ;
Wilson, Shannon ;
Kirpotin, Dmitri B. ;
Nishimura, Stephen L. ;
Broaddus, V. Courtney ;
Liu, Bin .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (03) :569-578
[10]   Effective quark antiquark potential in the quark gluon plasma from gravity dual models [J].
Antipin, Oleg ;
Burikham, Piyabut ;
Li, Jun .
JOURNAL OF HIGH ENERGY PHYSICS, 2007, (06)
12345678910